Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 23
Filtrar
1.
Acta Pharmacol Sin ; 40(4): 492-499, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-29950617

RESUMO

Myotoxicity is a significant factor contributing to the poor adherence and reduced effectiveness in the treatment of statins. Genetic variations and high drug plasma exposure are considered as critique causes for statin-induced myopathy (SIM). This study aims to explore the sequential influences of rosuvastatin (RST) pharmacokinetic and myopathy-related single-nucleotide polymorphisms (SNPs) on the plasma exposure to RST and its metabolites: rosuvastatin lactone (RSTL) and N-desmethyl rosuvastatin (DM-RST), and further on RST-induced myopathy. A total of 758 Chinese patients with coronary artery disease were enrolled and followed up SIM incidents for 2 years. The plasma concentrations of RST and its metabolites were determined through a validated ultra-performance liquid chromatography mass spectrometry method. Nine SNPs in six genes were genotyped by using the Sequenom MassArray iPlex platform. Results revealed that ABCG2 rs2231142 variations were highly associated with the plasma concentrations of RST, RSTL, and DM-RST (Padj < 0.01, FDR < 0.05). CYP2C9 rs1057910 significantly affected the DM-RST concentration (Padj < 0.01, FDR < 0.05). SLCO1B1 rs4149056 variant allele was significantly associated with high SIM risk (OR: 1.741, 95% CI: 1.180-2.568, P = 0.0052, FDR = 0.0468). Glycine amidinotransferase (GATM) rs9806699 was marginally associated with SIM incidents (OR: 0.617, 95% CI: 0.406-0.939, P = 0.0240, FDR = 0.0960). The plasma concentrations of RST and its metabolites were not significantly different between the SIM (n = 51) and control groups (n = 707) (all P > 0.05). In conclusion, SLCO1B1 and GATM genetic variants are potential biomarkers for predicting RST-induced myopathy, and their effects on SIM are unrelated to the high plasma exposure of RST and its metabolites.


Assuntos
Amidinotransferases/genética , Doença da Artéria Coronariana/tratamento farmacológico , Transportador 1 de Ânion Orgânico Específico do Fígado/genética , Doenças Musculares/induzido quimicamente , Rosuvastatina Cálcica/sangue , Amidinotransferases/sangue , Amidinotransferases/metabolismo , China , Doença da Artéria Coronariana/sangue , Doença da Artéria Coronariana/metabolismo , Variação Genética , Humanos , Transportador 1 de Ânion Orgânico Específico do Fígado/sangue , Transportador 1 de Ânion Orgânico Específico do Fígado/metabolismo , Doenças Musculares/genética , Polimorfismo de Nucleotídeo Único/genética , Rosuvastatina Cálcica/metabolismo , Rosuvastatina Cálcica/farmacocinética
2.
Genet Med ; 19(2): 256-263, 2017 02.
Artigo em Inglês | MEDLINE | ID: mdl-28055022

RESUMO

Disclaimer: These ACMG Standards and Guidelines are intended as an educational resource for clinical laboratory geneticists to help them provide quality clinical laboratory genetic services. Adherence to these standards and guidelines is voluntary and does not necessarily assure a successful medical outcome. These Standards and Guidelines should not be considered inclusive of all proper procedures and tests or exclusive of others that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, clinical laboratory geneticists should apply their professional judgment to the specific circumstances presented by the patient or specimen. Clinical laboratory geneticists are encouraged to document in the patient's record the rationale for the use of a particular procedure or test, whether or not it is in conformance with these Standards and Guidelines. They also are advised to take notice of the date any particular guideline was adopted, and to consider other relevant medical and scientific information that becomes available after that date. It also would be prudent to consider whether intellectual property interests may restrict the performance of certain tests and other procedures.Cerebral creatine deficiency syndromes are neurometabolic conditions characterized by intellectual disability, seizures, speech delay, and behavioral abnormalities. Several laboratory methods are available for preliminary and confirmatory diagnosis of these conditions, including measurement of creatine and related metabolites in biofluids using liquid chromatography-tandem mass spectrometry or gas chromatography-mass spectrometry, enzyme activity assays in cultured cells, and DNA sequence analysis. These guidelines are intended to standardize these procedures to help optimize the diagnosis of creatine deficiency syndromes. While biochemical methods are emphasized, considerations for confirmatory molecular testing are also discussed, along with variables that influence test results and interpretation.Genet Med 19 2, 256-263.


Assuntos
Amidinotransferases/deficiência , Erros Inatos do Metabolismo dos Aminoácidos/genética , Encefalopatias Metabólicas Congênitas/genética , Creatina/deficiência , Creatina/metabolismo , Guanidinoacetato N-Metiltransferase/deficiência , Deficiência Intelectual/genética , Transtornos do Desenvolvimento da Linguagem/genética , Deficiência Intelectual Ligada ao Cromossomo X/genética , Transtornos dos Movimentos/congênito , Proteínas da Membrana Plasmática de Transporte de Neurotransmissores/deficiência , Proteínas Repressoras/genética , Distúrbios da Fala/genética , Amidinotransferases/sangue , Amidinotransferases/líquido cefalorraquidiano , Amidinotransferases/genética , Amidinotransferases/urina , Erros Inatos do Metabolismo dos Aminoácidos/sangue , Erros Inatos do Metabolismo dos Aminoácidos/líquido cefalorraquidiano , Erros Inatos do Metabolismo dos Aminoácidos/urina , Encefalopatias Metabólicas Congênitas/sangue , Encefalopatias Metabólicas Congênitas/líquido cefalorraquidiano , Encefalopatias Metabólicas Congênitas/urina , Técnicas de Laboratório Clínico/métodos , Creatina/sangue , Creatina/líquido cefalorraquidiano , Creatina/genética , Creatina/urina , Deficiências do Desenvolvimento/sangue , Deficiências do Desenvolvimento/líquido cefalorraquidiano , Deficiências do Desenvolvimento/genética , Deficiências do Desenvolvimento/urina , Testes Genéticos/normas , Genética Médica/normas , Genômica , Guanidinoacetato N-Metiltransferase/sangue , Guanidinoacetato N-Metiltransferase/líquido cefalorraquidiano , Guanidinoacetato N-Metiltransferase/genética , Guanidinoacetato N-Metiltransferase/urina , Guias como Assunto , Humanos , Deficiência Intelectual/sangue , Deficiência Intelectual/líquido cefalorraquidiano , Deficiência Intelectual/urina , Transtornos do Desenvolvimento da Linguagem/sangue , Transtornos do Desenvolvimento da Linguagem/líquido cefalorraquidiano , Transtornos do Desenvolvimento da Linguagem/urina , Deficiência Intelectual Ligada ao Cromossomo X/sangue , Deficiência Intelectual Ligada ao Cromossomo X/líquido cefalorraquidiano , Deficiência Intelectual Ligada ao Cromossomo X/urina , Transtornos dos Movimentos/sangue , Transtornos dos Movimentos/líquido cefalorraquidiano , Transtornos dos Movimentos/genética , Transtornos dos Movimentos/urina , Proteínas da Membrana Plasmática de Transporte de Neurotransmissores/sangue , Proteínas da Membrana Plasmática de Transporte de Neurotransmissores/líquido cefalorraquidiano , Proteínas da Membrana Plasmática de Transporte de Neurotransmissores/genética , Proteínas da Membrana Plasmática de Transporte de Neurotransmissores/urina , Proteínas Repressoras/sangue , Proteínas Repressoras/líquido cefalorraquidiano , Proteínas Repressoras/urina , Distúrbios da Fala/sangue , Distúrbios da Fala/líquido cefalorraquidiano
4.
Amino Acids ; 47(9): 1893-908, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26031828

RESUMO

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthesis, whereas L-arginine (Arg) and L-homoarginine (hArg) serve as substrates for NO synthesis. ADMA and other methylated arginines are generally believed to exclusively derive from guanidine (N (G))-methylated arginine residues in proteins by protein arginine methyltransferases (PRMTs) that use S-adenosylmethionine (SAM) as the methyl donor. L-Lysine is known for decades as a precursor for hArg, but only recent studies indicate that arginine:glycine amidinotransferase (AGAT) is responsible for the synthesis of hArg. AGAT catalyzes the formation of guanidinoacetate (GAA) that is methylated to creatine by guanidinoacetate methyltransferase (GAMT) which also uses SAM. The aim of the present study was to learn more about the mechanisms of ADMA and hArg formation in humans. Especially, we hypothesized that ADMA is produced by N (G)-methylation of free Arg in addition to the known PRMTs-involving mechanism. In knockout mouse models of AGAT- and GAMT-deficiency, we investigated the contribution of these enzymes to hArg synthesis. Arg infusion (0.5 g/kg, 30 min) in children (n = 11) and ingestion of high-fat protein meals by overweight men (n = 10) were used to study acute effects on ADMA and hArg synthesis. Daily Arg ingestion (10 g) or placebo for 3 or 6 months by patients suffering from peripheral arterial occlusive disease (PAOD, n = 20) or coronary artery disease (CAD, n = 30) was used to study chronic effects of Arg on ADMA synthesis. Mass spectrometric methods were used to measure all biochemical parameters in plasma and urine samples. In mice, AGAT but not GAMT was found to contribute to plasma hArg, while ADMA synthesis was independent of AGAT and GAMT. Arg infusion acutely increased plasma Arg, hArg and ADMA concentrations, but decreased the plasma hArg/ADMA ratio. High-fat protein meals acutely increased plasma Arg, hArg, ADMA concentrations, as well as the plasma hArg/ADMA ratio. In the PAOD and CAD studies, plasma Arg concentration increased in the verum compared to the placebo groups. Plasma ADMA concentration increased only in the PAOD patients who received Arg. Our study suggests that in humans a minor fraction of free Arg is rapidly metabolized to ADMA and hArg. In mice, GAMT and N (G)-methyltransferases contribute to ADMA and hArg synthesis from Arg, whereas AGAT is involved in the synthesis of hArg but not of ADMA. The underlying biochemical mechanisms remain still elusive.


Assuntos
Arginina/análogos & derivados , Arginina/administração & dosagem , Doença da Artéria Coronariana/sangue , Homoarginina/biossíntese , Doença Arterial Periférica/sangue , Adolescente , Adulto , Amidinotransferases/sangue , Amidinotransferases/deficiência , Amidinotransferases/genética , Amidinotransferases/metabolismo , Erros Inatos do Metabolismo dos Aminoácidos/sangue , Erros Inatos do Metabolismo dos Aminoácidos/tratamento farmacológico , Erros Inatos do Metabolismo dos Aminoácidos/genética , Animais , Arginina/biossíntese , Criança , Doença da Artéria Coronariana/tratamento farmacológico , Doença da Artéria Coronariana/genética , Deficiências do Desenvolvimento/sangue , Deficiências do Desenvolvimento/tratamento farmacológico , Deficiências do Desenvolvimento/genética , Feminino , Guanidinoacetato N-Metiltransferase/sangue , Guanidinoacetato N-Metiltransferase/deficiência , Guanidinoacetato N-Metiltransferase/genética , Guanidinoacetato N-Metiltransferase/metabolismo , Humanos , Deficiência Intelectual/sangue , Deficiência Intelectual/tratamento farmacológico , Deficiência Intelectual/genética , Transtornos do Desenvolvimento da Linguagem/sangue , Transtornos do Desenvolvimento da Linguagem/tratamento farmacológico , Transtornos do Desenvolvimento da Linguagem/genética , Masculino , Camundongos , Camundongos Knockout , Pessoa de Meia-Idade , Transtornos dos Movimentos/sangue , Transtornos dos Movimentos/congênito , Transtornos dos Movimentos/tratamento farmacológico , Transtornos dos Movimentos/genética , Doença Arterial Periférica/tratamento farmacológico , Doença Arterial Periférica/genética , Distúrbios da Fala/sangue , Distúrbios da Fala/tratamento farmacológico , Distúrbios da Fala/genética
5.
Clin Chim Acta ; 436: 160-8, 2014 Sep 25.
Artigo em Inglês | MEDLINE | ID: mdl-24877651

RESUMO

BACKGROUND: To develop an accurate stable isotope dilution assay for simultaneous quantification of creatine metabolites ornithine, arginine, creatine, creatinine, and guanidinoacetate in very small blood sample volumes to study creatine metabolism in mice. METHODS: Liquid-chromatography (C18) tandem mass spectrometry with butylation was performed in positive ionization mode. Stable isotope dilution assay with external calibration was applied to three different specimen types, plasma, whole blood and dried blood spot (DBS). RESULTS: Analytical separation, sensitivity, accuracy, and linearity of the assay were adequate. The stable isotope dilution assay in plasma revealed no significant bias to gold standard methods for the respective analytes. Compared to plasma, we observed an overestimate of creatine and creatinine (2- to 5-fold and 1.2- to 2-fold, respectively) in whole-blood and DBS, and an underestimate of arginine (2.5-fold) in DBS. Validation of the assay in mouse models of creatine deficiency revealed plasma creatine metabolite pattern in good accordance with those observed in human GAMT and AGAT deficiency. Single dose intraperitoneal application of ornithine in wild-type mice lead to fast ornithine uptake (Tmax ≤ 10 min) and elimination (T1/2=24 min), and a decline of guanidinoacetate. CONCLUSION: The assay is fast and reliable to study creatine metabolism and pharmacokinetics in mouse models of creatine deficiency.


Assuntos
Amidinotransferases/deficiência , Erros Inatos do Metabolismo dos Aminoácidos/sangue , Creatina/sangue , Creatina/deficiência , Teste em Amostras de Sangue Seco/métodos , Guanidinoacetato N-Metiltransferase/deficiência , Deficiência Intelectual/sangue , Transtornos do Desenvolvimento da Linguagem/sangue , Transtornos dos Movimentos/congênito , Plasma/metabolismo , Distúrbios da Fala/sangue , Amidinotransferases/sangue , Amidinotransferases/metabolismo , Erros Inatos do Metabolismo dos Aminoácidos/metabolismo , Animais , Cromatografia Líquida , Creatina/metabolismo , Deficiências do Desenvolvimento/sangue , Deficiências do Desenvolvimento/metabolismo , Modelos Animais de Doenças , Guanidinoacetato N-Metiltransferase/sangue , Guanidinoacetato N-Metiltransferase/metabolismo , Humanos , Deficiência Intelectual/metabolismo , Isótopos/química , Transtornos do Desenvolvimento da Linguagem/metabolismo , Limite de Detecção , Modelos Lineares , Camundongos , Transtornos dos Movimentos/sangue , Transtornos dos Movimentos/metabolismo , Reprodutibilidade dos Testes , Distúrbios da Fala/metabolismo , Espectrometria de Massas em Tandem
6.
Mol Genet Metab ; 109(3): 260-8, 2013 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23660394

RESUMO

Cerebral creatine deficiency syndromes (CCDS) are a group of inborn errors of creatine metabolism that involve AGAT and GAMT for creatine biosynthesis disorders and SLC6A8 for creatine transporter (CT1) deficiency. Deficiencies in the three enzymes can be distinguished by intermediate metabolite levels, and a definitive diagnosis relies on the presence of deleterious mutations in the causative genes. Mutations and unclassified variants were identified in 41 unrelated patients, and 22 of these mutations were novel. Correlation of sequencing and biochemical data reveals that using plasma guanidinoacetate (GAA) as a biomarker has 100% specificity for both AGAT and GAMT deficiencies, but AGAT deficiency has decreased sensitivity in this assay. Furthermore, the urine creatine:creatinine ratio is an effective screening test with 100% specificity in males suspected of having creatine transporter deficiency. This test has a high false-positive rate due to dietary factors or dilute urine samples and lacks sensitivity in females. We conclude that biochemical screening for plasma GAA and measuring of the urine creatine:creatinine ratio should be performed for suspected CCDS patients prior to sequencing. Also, based on the results of this study, we feel that sequencing should only be considered if a patient has abnormal biochemical results on repeat testing.


Assuntos
Amidinotransferases/deficiência , Erros Inatos do Metabolismo dos Aminoácidos/diagnóstico , Encefalopatias Metabólicas Congênitas/diagnóstico , Creatina/deficiência , Guanidinoacetato N-Metiltransferase/deficiência , Deficiência Intelectual/diagnóstico , Transtornos do Desenvolvimento da Linguagem/diagnóstico , Deficiência Intelectual Ligada ao Cromossomo X/diagnóstico , Transtornos dos Movimentos/congênito , Proteínas da Membrana Plasmática de Transporte de Neurotransmissores/deficiência , Distúrbios da Fala/diagnóstico , Amidinotransferases/sangue , Amidinotransferases/química , Amidinotransferases/genética , Amidinotransferases/metabolismo , Erros Inatos do Metabolismo dos Aminoácidos/genética , Erros Inatos do Metabolismo dos Aminoácidos/metabolismo , Encefalopatias Metabólicas Congênitas/genética , Encefalopatias Metabólicas Congênitas/metabolismo , Creatina/genética , Creatina/metabolismo , Creatinina/urina , Deficiências do Desenvolvimento/diagnóstico , Deficiências do Desenvolvimento/genética , Deficiências do Desenvolvimento/metabolismo , Feminino , Guanidinoacetato N-Metiltransferase/sangue , Guanidinoacetato N-Metiltransferase/genética , Guanidinoacetato N-Metiltransferase/metabolismo , Humanos , Deficiência Intelectual/genética , Deficiência Intelectual/metabolismo , Transtornos do Desenvolvimento da Linguagem/genética , Transtornos do Desenvolvimento da Linguagem/metabolismo , Masculino , Proteínas de Membrana Transportadoras/genética , Deficiência Intelectual Ligada ao Cromossomo X/genética , Deficiência Intelectual Ligada ao Cromossomo X/metabolismo , Modelos Moleculares , Transtornos dos Movimentos/diagnóstico , Transtornos dos Movimentos/genética , Transtornos dos Movimentos/metabolismo , Mutação , Fenótipo , Proteínas da Membrana Plasmática de Transporte de Neurotransmissores/genética , Proteínas da Membrana Plasmática de Transporte de Neurotransmissores/metabolismo , Conformação Proteica , Distúrbios da Fala/genética , Distúrbios da Fala/metabolismo , Síndrome
7.
FEBS Lett ; 586(20): 3653-7, 2012 Oct 19.
Artigo em Inglês | MEDLINE | ID: mdl-23010440

RESUMO

Low plasma homoarginine has emerged as a risk marker for cardiovascular disease. We exploited cells of a patient with a rare inborn error of metabolism to explore potential pathways of homoarginine synthesis, using stable isotopes and mass spectrometry. Control lymphoblasts, as opposed to lymphoblasts from an arginine:glycine amidinotransferase (AGAT)-deficient patient, were able to synthesize homoarginine from arginine and lysine. In contrast, in a patient with a deficiency of the urea cycle enzyme argininosuccinate synthase, plasma homoarginine was not decreased. We conclude that promiscuous activity of AGAT, a key enzyme in creatine synthesis, plays a pivotal role in homoarginine synthesis.


Assuntos
Amidinotransferases/metabolismo , Doenças Cardiovasculares/metabolismo , Homoarginina/biossíntese , Amidinotransferases/sangue , Amidinotransferases/deficiência , Erros Inatos do Metabolismo dos Aminoácidos/sangue , Erros Inatos do Metabolismo dos Aminoácidos/metabolismo , Deficiências do Desenvolvimento/sangue , Deficiências do Desenvolvimento/metabolismo , Homoarginina/sangue , Humanos , Recém-Nascido , Deficiência Intelectual/sangue , Deficiência Intelectual/metabolismo , Masculino , Fatores de Risco , Distúrbios da Fala/sangue , Distúrbios da Fala/metabolismo , Especificidade por Substrato
10.
Biull Eksp Biol Med ; 108(10): 428-30, 1989 Oct.
Artigo em Russo | MEDLINE | ID: mdl-2597753

RESUMO

The influence of regulatory peptides (somatostatin, calcitonin, and dalargin) on xanthine oxidase activity and lipid peroxidation level in pancreatic tissues as well as on the release of pancreatic enzymes (alpha-amylase, trypsin, lipase, and transamidinase) into blood was studied in 205 rats with experimental acute pancreatitis. Somatostatin and dalargin were shown to have obvious antioxidant effect seen by reduced xanthine oxidase activity and MDA level. All studied peptides stimulate reduced release of pancreatic enzymes. Particularly, reduction of dalargin and somatostatin is caused by inhibition of their synthesis as well as by pancreas protective effect of the peptides. Release of enzymes reduced by calcitonin is probably associated only with inhibition of secretory activity of the pancreas.


Assuntos
Calcitonina/farmacologia , Leucina Encefalina-2-Alanina/análogos & derivados , Encefalina Leucina/análogos & derivados , Pâncreas/efeitos dos fármacos , Pancreatite/fisiopatologia , Somatostatina/farmacologia , Simpatolíticos/farmacologia , Doença Aguda , Amidinotransferases/sangue , Animais , Encefalina Leucina/farmacologia , Lipase/sangue , Peroxidação de Lipídeos , Masculino , Pâncreas/enzimologia , Pâncreas/fisiopatologia , Ratos , Tripsina/sangue , Xantina Oxidase/metabolismo , alfa-Amilases/sangue
11.
Exp Clin Endocrinol ; 92(1): 37-42, 1988 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-2976378

RESUMO

This study investigates the diabetes-induced lesions in liver and kidney and in addition the possible side effects of the diabetogenic substance streptozotocin (SR) on these organs in non-diabetic animals. 5-week-old female Wistar rats were injected 65 or 130 mg SR/kg body mass. Some animals of the drug group did not become hyperglycemic; thus it was possible to separate the drug effect from the diabetic influence on liver and kidney. In serum investigations some metabolic changes concerning the activities of the liver enzymes aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase and the concentrations of urea and creatinine up to 30 days after drug application were studied. SR in hyperglycemic animals causes a time and dose dependent rise in all investigated parameters. Also in normoglycemic rats a significant increase in alkaline phosphatase and in creatinine was observed after 10 days. After 21 and 30 days there were no differences compared to untreated control rats, whereas elevated levels were observed in the hyperglycemic rats. Thus our results support the view of a short damaging effect of SR on liver and kidney without inducing a diabetic state; in hyperglycemic rats the damaging effect is more pronounced.


Assuntos
Amidinotransferases/sangue , Creatina/sangue , Estreptozocina/farmacologia , Ureia/sangue , Alanina Transaminase/sangue , Fosfatase Alcalina/sangue , Animais , Aspartato Aminotransferases/sangue , Feminino , Ratos , Ratos Endogâmicos
12.
Med Pr ; 38(3): 167-74, 1987.
Artigo em Polonês | MEDLINE | ID: mdl-2890076

RESUMO

The activities of GGT (EC 2.3.2.1.) and glycine transaminidase (EC 2.6.2.1.) increased in all studied groups after at minimum four years of exposure to: acetobenzene, furfurol, ethylene--derivatives, polypropylene and butadiene. Besides these universal indicators the specific ones were found for a particular group of exposure: for acetobenzene--sialic acid, haptoglobine and IgA, for furfurol--sialic acid and haptoglobine, for ethylene--derivatives--haptoglobine, ceruloplasmine and the activity of arginase of the red blood cells, for polypropylene--IgA, for butadiene--proteolytic activity. These changes are treated as a manifestation of adaptive processes--the answer of the body to the environmental stimuli but not as the signs of early damage. The need of verification of the results by prospective studies is stressed.


Assuntos
Indústria Química , Doenças Profissionais/induzido quimicamente , Petróleo/efeitos adversos , Adulto , Amidinotransferases/sangue , Ensaios Enzimáticos Clínicos , Ativação Enzimática/efeitos dos fármacos , Humanos , Pessoa de Meia-Idade , Doenças Profissionais/diagnóstico , gama-Glutamiltransferase/sangue
13.
Med Pr ; 38(2): 108-14, 1987.
Artigo em Polonês | MEDLINE | ID: mdl-2888004

RESUMO

Eleven non-routine biochemical and clinical indicators (selected of 26 preliminarily estimated) in Petrochemical Plant workers and in controls, localized in an increasing distance from the Plant (3-18-40 km), have been measured. Even in the 3 km distance, no effects of the Petrochemical Plant have been found. All the exposed groups exhibited changes in enzymes GGT and TA. We estimate these indicators as universal. The concentration of haptoglobin (Hp) changed in 3 groups, whereas sialic acid and arginase--in 2 exposed groups.


Assuntos
Indústria Química , Doenças Profissionais/induzido quimicamente , Petróleo/toxicidade , Amidinotransferases/sangue , Arginase/sangue , Feminino , Haptoglobinas/análise , Humanos , Masculino , Ácido N-Acetilneuramínico , Doenças Profissionais/diagnóstico , Ácidos Siálicos/sangue , gama-Glutamiltransferase/sangue
14.
Vestn Khir Im I I Grek ; 136(4): 29-33, 1986 Apr.
Artigo em Russo | MEDLINE | ID: mdl-3750641

RESUMO

In diagnosis of acute pancreatitis of special importance is determination of the activity of transamidinase, phospholipase A, lipase, concentration of copper, calcium and triglycerides in blood serum as well as laparoscopy with biopsy and local thermometry of the pancreas. The dosage of 5-fluoruracil in the complex treatment of patients should be differentiated corresponding to the form of the disease: 3 mg/kg in the endomatous form, 5 mg/kg in the destructive form. The general lethality was 1.4%. In conservative treatment there were no lethal outcomes.


Assuntos
Pancreatite/diagnóstico , Doença Aguda , Adulto , Amidinotransferases/sangue , Cálcio/sangue , Ensaios Enzimáticos Clínicos , Terapia Combinada , Cobre/sangue , Feminino , Humanos , Lipase/sangue , Masculino , Pessoa de Meia-Idade , Testes de Função Pancreática , Pancreatite/terapia , Fosfolipases A/sangue , Termografia , Triglicerídeos/sangue
15.
Biull Eksp Biol Med ; 91(10): 498-501, 1981 Oct.
Artigo em Russo | MEDLINE | ID: mdl-6976193

RESUMO

Histological and electron microscopic study of the pancreas and biochemical determination of pancreatic enzymes in blood serum were performed in animals with experimental pancreonecrosis and after the treatment with 5-fluorouracil. The treatment resulted in the decreased secretion of pancreatic acinus tissue, diminution of destructive and inflammatory lesions and the decreased levels of trypsin, alpha-amylase and transamidinase. It is suggested that 5-fluorouracil may be used in the combined treatment of acute pancreonecrosis.


Assuntos
Fluoruracila/uso terapêutico , Pâncreas/ultraestrutura , Pancreatopatias/tratamento farmacológico , Doença Aguda , Amidinotransferases/sangue , Animais , Masculino , Microscopia Eletrônica , Necrose , Pancreatopatias/patologia , Ratos , Tripsina/sangue , alfa-Amilases/sangue
16.
Am J Dis Child ; 135(7): 628-30, 1981 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-6787913

RESUMO

A 10-month-old infant with hypoplasia of the intestinal mucosa had the fat overload syndrome develop while receiving intravenous fat emulsion at a dosage of 5 g/kg/day of fat for five weeks. This syndrome was characterized by fever, jaundice, easy bruisability, increased levels of serum transaminases, conjugated hyperbilirubinemia, and abnormal results of clotting studies. Management consisted of withdrawal of parenteral nutrition for 72 hours, followed by gradual reinstitution of protein and subsequent introduction of fat at a lower dosage.


Assuntos
Hiperlipidemias/etiologia , Nutrição Parenteral Total/efeitos adversos , Nutrição Parenteral/efeitos adversos , Amidinotransferases/sangue , Testes de Coagulação Sanguínea , Feminino , Febre/etiologia , Humanos , Lactente , Enteropatias/terapia , Icterícia/etiologia
17.
Artigo em Francês | MEDLINE | ID: mdl-611596

RESUMO

The authors studied four children with Reye's syndrome aged 16 months, 6 years, 8 years and 11 years respectively with severe liver failure and progressive coma. The laboratory investigations in all of them showed a marked elevation of serum transaminases, hyperammoniaemia and a prolongation of the prothrombin time. The electroencephalograms showed a grossly abnormal picture with generalised continuous delta activity. Three children survived with return to normal of the liver function tests whilst the fourth child died. In the last two patients an electroencephalogram carried out every six hours has enabled certain prognostic features to be determined. Improvement in the E.E.G. correlates closely with clinical improvement and vice versa. The authors also advocate serial E.E.G. recordings in Reye's syndrome. The role of hyperammonaemia in the genesis of encephalopathy and the electroencephalographic changed is discussed. The role played by raised intracranial pressure is stressed and the importance of controlling it in order to prevent further damage and improve the prognosis of this serious illness.


Assuntos
Síndrome de Reye/fisiopatologia , Amidinotransferases/sangue , Amônia/sangue , Criança , Eletroencefalografia , Eletrofisiologia , Feminino , Humanos , Lactente , Pressão Intracraniana , Masculino , Tempo de Protrombina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA